Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference

4/9/24 7:32:40 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TRVI alert in real time by email

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.

Get the next $TRVI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRVI

Date	Price Target	Rating	Analyst
9/9/2024	$6.00 → $7.00	Outperform	Leerink Partners
8/30/2024	$6.00	Buy	H.C. Wainwright
8/30/2024	$9.00	Outperform	Raymond James
6/13/2024	$7.00	Buy	Rodman & Renshaw
4/12/2023	$6.00	Buy	B. Riley Securities
11/22/2022	$6.00	Outperform	SVB Leerink
11/11/2021	$10.00 → $8.00	Buy	Needham
8/13/2021	$12.00 → $10.00	Buy	Needham

More analyst ratings

$TRVI
Financials

Live finance-specific insights

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
11/6/24 4:05:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2024. www.trevithe
10/30/24 4:05:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 8, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the tr
8/8/24 4:05:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care

$TRVI
Press Releases

Fastest customizable press release news feed in the world

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
11/6/24 4:05:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2024. www.trevithe
10/30/24 4:05:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc
10/21/24 7:30:00 AM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO). www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte
9/30/24 5:30:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d
4/2/24 7:30:00 AM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer
David Clark, MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.
11/14/22 4:05:00 PM ET
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care

Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference

Chat with this insight

Recent Analyst Ratings for $TRVI

$TRVI Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

$TRVI Financials

Live finance-specific insights

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

$TRVI Market Insights

Live Market Insights

Rodman & Renshaw Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $7

12 Health Care Stocks Moving In Thursday's After-Market Session

Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

$TRVI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners resumed coverage on Trevi Therapeutics with a new price target

H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target

Raymond James initiated coverage on Trevi Therapeutics with a new price target

$TRVI Press Releases

Fastest customizable press release news feed in the world

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

$TRVI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Development Officer Cassella James V

President & CEO Good Jennifer L exercised 6,059 shares at a strike of $1.43 and sold $18,371 worth of shares (6,059 units at $3.03) (SEC Form 4)

President & CEO Good Jennifer L exercised 55,121 shares at a strike of $1.43 and sold $170,193 worth of shares (55,121 units at $3.09) (SEC Form 4)

$TRVI SEC Filings

SEC Form 10-Q filed by Trevi Therapeutics Inc.

Trevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Trevi Therapeutics Inc. filed SEC Form 8-K: Other Events

$TRVI Leadership Updates

Live Leadership Updates

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Recent Analyst Ratings for
$TRVI

$TRVI
Large Ownership Changes

$TRVI
Financials

$TRVI
Market Insights

$TRVI
Analyst Ratings

$TRVI
Press Releases

$TRVI
Insider Trading

$TRVI
SEC Filings

$TRVI
Leadership Updates